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Abstract
CD36, an 88 kDa membrane glycoprotein, is found in several cell types and it has been
characterized to have two hydrophobic domains at their N- and C-termini which are essential for
protein folding and targeting. In this study, we first tagged the green fluorescent protein (GFP) to
both the N- and C-termini of huCD36 and investigated their cellular expression and influences on
lipoprotein and plasmodium falciparium parasitized erythrocytes (pRBC) binding. Our work
revealed that huCD36 proteins are expressed normally irrespective of the GFP tag presence at
either the N- or C-termini. However, the two recombinant proteins showed discrepancy in uptake
and surface-binding of OxLDL but they did not affect pRBC binding. These results suggested that
the interaction between oxLDL and CD36 could be blocked using recombinant proteins and this
may be useful in potential control of the trafficking of modified lipoproteins into monocytes leading
to atherogenesis.
Background
Receptor-mediated binding and uptake of oxidized low
lipoprotein (OxLDL) by microphages has been implicated
in foam cell formation in the process of atherosclerosis
[1,2], in which oxidation of LDL is a critical early event in
the pathogenesis and OxLDL is the primal source of lipid
that accumulates within cells of the atherosclerotic lesion
[1,3,4]. There are at least two major classes of mammalian
monocyte and microphage scavenger receptors, termed as
SR-A and SR-B, and they are involved in binding/uptake
of oxLDL to macrophages and endothelial cells leading to
atherosclerotic pathogenesis, and they also function in the
recognition, and clearance of damaged tissues or apop-
totic cells [5-7].
CD36, an 88 kDa membrane glycoprotein, is found in
several cell types, such as platelets, monocytes, macro-
phages and endothelial cells [8-12]. CD36 has been
reported to be a multifunctional receptor and it recognizes
a wide variety of ligands including OxLDL [13], throm-
bospondin [14,15], collagen [16,17], apoptotic neu-
trophils [18,19], Plasmodium falciparum-infected
erythrocytes [20-22] and anionic phospholipids [23,24].
Further studies demonstrated that CD36 expressed in
COS 7 or Sf9 cells functioned as a high-affinity receptor
not only for OxLDL, but also for HDL, LDL and VLDL
[10,25]. Several regions of CD36 have been implicated as
binding domains for its different ligands, including
amino acids 28–93 as the OxLDL binding domain [26],
and amino acids 93–120 as the thrombospondin binding
region [27].
CD36 protein has been characterized to have two hydro-
phobic domains at their N- and C-termini and these
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domains are essential for protein folding and targeting
[28]. However, Pucent Navazo et al (1996) suggested that
only the transmembrane domain and the C-terminal end
of CD36 function in membrane anchoring [29]. Even
though different ligand-binding domains on CD36 mole-
cules have been characterized, there specific functions still
remain inconclusive. To this end, several attempts were
made to define domains for specific ligands and their
functions on CD36. Pearce et al. (1998) used a series of
GST/CD36 fusion proteins to define the domains of
CD36 that specifically bind to Ox-LDL [26]. Stewart and
Nagarajan (2006) created a soluble CD36 cDNA by
replacing a signal peptide sequence of a type I membrane
protein, CD59, at the N-terminus and a human IgG1
CVH2-CH3 Fc domain at the C-terminus of CD36. Their
results confirmed that the chimeric sCD36-Ig is secreted
and folded correctly, and it competitively inhibits oxLDL
binding to membrane-expressed CD36 and oxLDL-
induced monocyte adhesion [30,31]. In other studies, dif-
ferent ligand-binding domains of CD36 molecules were
detected immunologically with a large group of antibod-
ies raised against CD36 [29,32-34].
In this study, we first tagged the green fluorescent protein
to both the N- and C-termini of huCD36 and investigated
their cellular expression and influences on lipoprotein
and pRBC binding. Our work revealed that huCD36 pro-
teins are expressed normally irrespective of the GFP tag
presence at either the N- or C-termini. However, the two
recombinant proteins showed discrepancy in uptake and
surface-binding of OxLDL but they did not affect pRBC
binding. These results suggested that the interaction
between oxLDL and CD36 can be blocked using recom-
binant proteins and this may be useful in potential con-
trol of the trafficking of modified lipoproteins into
monocytes leading to atherogenesis.
Methods
Chemicals and materials
pEGFP-C3 and pEGFP-N3 plasmid DNA were purchased
from Clontech Laboratories, Inc. (Pulo Alto, CA, USA).
TheExgen 500 transfection kit and restriction enzymes,
KphI and HindIII were from Fermentas (Burlinton, ON,
Canada). Taq DNA polymerase and nucleotide mix were
from Invitrogen Canada (Burlington, ON). Plasmid DNA
purification kits were from Qiagen. Anti-CD36 antibody
was from Immunotech, Bekiman Coulter (USA). CHO
cell lines and stable transfected CHO-CD36 cells were cul-
tured and maintained as described [20].
Construction of pEGFP-C3-CD36 and pEGFP-N3-CD36
The vectors, pEGFP-C3 and pEGFP-N3, were cut at clon-
ing sites with restriction enzymes, KpnI and Hind III and
then purified with Qiagen DNA purification kit. The cod-
ing sequence of huCD36 was PCR amplified from
pCDNA3-huCD36. For the pEGFP-C3-CD36 construct,
two primers were used as 5' ATTAAGCTTATGGGCTGT-
GACCGGAACTGTG and 5' ATTGGTACCTTATTTTATT-
GTTTTCGATCTGCA. While for construction of pEGFP-
N3-CD36, a stop codon at C-terminal of CD36 was
deleted by using the backward primer as 5' ATTGGTAC-
CTTTTATTGTTTTCGATCTGCA. For both PCR-amplified
CD36 products, a Hind III site was created at N-terminal
and a Kpn I site was created at the C-terminus. Both PCR-
CD36 products were restriction-enzyme cut with Hind III
and Kpn I and gel-purified. The purified PCR-CD36 was
inserted into either peGFP-C3 or pEGFP-N3 vectors by
normal ligation procedures. Ligated pEGFP-C3-CD36 and
pEGFP-N3-CD36 were transformed into Xl-1Blue compe-
tent cells and amplified. Recombinant DNAs were
sequenced to determine whether the CD36 coding
sequences were inserted correctly into the vectors.
Transfection and recombinant protein expression assays
CHO cells were seeded on coverslips and cultured in 12-
well plates in RPM1640 medium overnight to allow cells
to grow to about 70% confluence at the time of transfec-
tion. The recombinant plasmid DNAs, either pEGFP-C3-
CD36 or pEGFP-N3-CD36, were highly purified to the
OD260/OD280 ratio of at least 1.8 or larger. For transfec-
tion, ExGen 500 in vitro transfection kit (Invitrogen) was
used according to the manufacturer's instructions. Briefly,
4 μg DNA of pEGFP-C3-Cd36 or pEGFP-N3-CD36, were
diluted in 50 μl of 150 mM NaCl mixed with 50 μl of
diluted Exgen 500 solution (1: 6 with 150 mM NaCl), and
incubated for 10 min, and then the mixtures were added
to each well with 0.9 ml of fresh RPM1640 medium. The
transfected cells were cultured for 48 hours. Transfected
fusion gene expression was assayed either with flow
cytometery or confocal microscopy.
Assays of dil-oxLDL binding
After transfection for 48 hours, cells were assayed for
oxLDL binding. For uptaking assays, 1 ml of fresh
RPM1640 medium was replaced in each well and a desig-
nated amount of Dil-oxLDL was directly added to each
well and remained in culture at 37°C for 2 – 4 hours. Cells
were then washed twice with PBS and fixed with 4% for-
maldehyde in PBS for 15 min. After washing several times
with PBS, cells were mounted onto slides. For surface
binding assay, cells after 48 h post-trasnfection were fixed
with 4% formaldehyde for 20 min. Upon washing three
times with PBS, cells were incubated with Dil-oxLDL at 10
μg/ml in PBS buffer at room temperature for 4 hours. After
washing three times, the amount of bounded dil-oxLDL
was assayed by flow cytometery or confocal microscopy.Lipids in Health and Disease 2007, 6:24 http://www.lipidworld.com/content/6/1/24
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Immunofluorecent staining of transfected cells with anti-
CD36 antibody
To assay if recombinant CD36 could be normally
expressed, cells after transfection with either pEGFP-C3-
CD36 or pEGFP-N3-CD36 for 48 hours, were immnos-
tained with anti-CD36 antibody at 1:100 in blocking
buffer (1% BSA and 0.1% Tween-20 in PBS) at room tem-
perature for 4 hours, or at 4°C overnight. Immediately
after primary antibody incubation, cells were washed
three times and counterstained with TRIC-conjugated
anti-mouse IgG secondary antibody at 1:500 for two
hours. After washing three times with PBS, stained cells
were assayed by either flow cytometery or confocal micro-
scopy.
pRBC adhesion assays
Adhesion assays were carried out as described by Crandall
et al (1999) [20]. Transfected cells were fixed in 4% for-
maldehyde in PBS for 15 min and then rinsed three times
with BTS. Adhension assays using a total volume of 300 μl
of infected blood were carried out. The erythrocytes were
kept in suspension by continuous agitation and incubated
with the target cells for 90 min. Adhesion was quantitated
by direct microscopic observation of transfected cells of
either pEGFP-C3-CD36 or pEGFP-N3-CD36. Cells trans-
fected with only GFP were used as control. Three inde-
pendent experiments were done and data points represent
the mean values with the standard error of the mean indi-
cated by the mean bars.
Results
Construction and expression of hCD36-GFP fusion 
proteins in CHO cells
The scavenger receptor CD36 is a 78 – 88 kDa plasma
membrane glycoprotein and acts as a receptor for OxLDL
and acetylated LDL in vitro [10,35,36]. The coding
sequences of hCD36 from base 211 to base 1630 (1439
bp) were PCR-amplified and inserted into both pEGFP-C3
and pEGFP-N3 multiple cloning sites at Hind III and Kpn
I (Fig. 1A). The recombinant DNAs were twice confirmed
by DNA sequencing and restriction enzyme re-cut (Fig.
1B) and the results proved that the coding sequences of
hCD36 were inserted in frame in both plasmids.
To verify if recombinant GFP-CD36 could be normally
expressed in vivo, the fusion plasmids, the pEGFP-C3-
CD36 and pEGFP-N3-CD36, were transfected into CHO
cells with an ExGen 500 kit (Clontech). After 48 hours of
incubation, transfected cells were immunofluorescently
stained with anti-CD36 antibody, counter stained with
TRIC-conjugated secondary antibody, and then either
directly viewed under a fluorescent microscope or assayed
by flow cytometery. As showing in Fig. 2, GFP were well
expressed with either of the recombinant plasmids and
the CD36 proteins were also normally expressed. Quanti-
tative results by flow cytrometry demonstrated that CD36
proteins in pEGFP-N3-CD36 is about 30% stronger than
that in pEGFP-C3-CD36 plasmids (Fig. 3).
pEGFP-C3-CD36 limited OxLDL binding but not by 
pEGFP-N3-CD36
As CD36 is a receptor for oxLDL, we wondered if, in its
GFP-recombinant derivatives, the tag altered its affinity to
binding oxLDL. To test this, CHO cells were transfected
with either of the four plasmid DNAs, pEGFP-C3 and
pEGFP-N3, pEGFP-C3-CD36, pEGFP-N3-Cd36, and
pCDNA3-hCd36. After 48 hours of incubation, the trans-
fected cells were assayed for Dil-oxLDL binding by uptak-
ing. As shown in Fig. 4, for cells transfected with the
control GFP plasmid, only a weak background of OxLDL
was seen (Fig. 4, top panel); Cells transfected with pEGFP-
N3-Cd36 showed a normal amount of dil-oxLDL binding
(Fig. 4, second panel from the top). However, once trans-
fected with peGFP-C3-CD36, only a very weak staining of
Dil-oxLDL was seen (Fig. 4, the second panel from the
Schematic diagram of p-EGFP-C3-CD36 and peGFP-N3- Cd36 constructs Figure 1
Schematic diagram of p-EGFP-C3-CD36 and peGFP-
N3-Cd36 constructs. A, the coding sites of vectors, 
pEGFP-C3 and pEGFP-N3, were restriction enzymatically cut 
with both Hind III and Kpn I and the DNA fragments were 
purified. The inserts, PCR-amplified hCD36 coding 
sequences after purification, were ligated into the vectors, 
resulted in recombinant constructs of pEGFP-C3-CD36 or 
pEGFP-N3-CD36. B, 2% agarose gel to confirm the DNA 
constructs. Lane 1 and 2, Hind III and Kpn I cut and then 
purified pEGFP-C3 and pEGFP-N3 plasmid DNAs; Lane 3, 
purified PCR-amplified huCD36 cDNAs; Lane 4, PEGFP-C3-
huCD36 constructs; Lane 5, pEGFP-N3-huCD36 constructs; 
Lane 6 and 7 are re-digested pEGF-C3-hCD36 and pEGFP-
N3-hCD36 with Hind III and Kpn I. Lane 8, 1 Kb DNA mark-
ers.Lipids in Health and Disease 2007, 6:24 http://www.lipidworld.com/content/6/1/24
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bottom), which indicated that GFP tagged to different
ends of CD36 functionally altered the property of binding
OxLDL. Cells transfected with CD36 alone (pCDNA3-
CD36) showed a strong Dil-oxLDL binding.
Further, we hypothesized that the differences in Dil-
oxLDL binding between the two ends of GFP-tagged cD36
are cytoplasmically affected by over-expressed GFP. If this
is true, oxLDL should be relatively similar to those in sur-
face binding. To the ends, transfected cells were first fixed
with 4% formaldehyde and then incubated with Dil-
oxLDL to lead to them sorely surface binding. As seen in
Fig. 5, there no much change was seen on cells transfected
with either pEGFP-N3-Cd36, pCDNA3-CD36, pEGFP-N3,
controls in dil-oxLDL binding between two binding assay
methods (Fig. 5). However, in pEGFP-C3-CD36 trans-
fected cells, the amount of bound OxLDL in surface bind-
ing was increased to about 60%, compared to uptaking
(Fig. 5, panel pEGFP-C3-CD36).
Recombinant GFP-tagged CD36 doesn't change the 
property of pRBCs binding
As reported early, CD36 directly mediates cytoadherence
of plasmodium falciparium parasitized erythrocytes [20].
We investigated whether recombinant GFPCD36 retains
its property of pRBCs adherence. As shown in Fig. 6, cells
transfected with either pEGFP-C3-CD36 or pEGFP-N3-
CD36 displayed normal pRBCs adherence (Fig. 6, panels
pEGFP-C3-CD36 and pEGFP-N3-CD36). However, no
pRBCs binding was observed when pEGFP-C3 or pEGFP-
N3 vector alone was transfected (Fig. 6, top panel).
Discussion
In the present study, we first successfully created the
fusion constructs of GFP to huCD36 at both the N- and C-
termini, termed as pEGFP-C3-huCD36 and pEGFP-N3-
CD36. Both constructs, as well as GFP-encoding plasmid
and the CD36 cDNA clone, were normally expressed once
they were transiently-transfected into CHO cells. By
immunostaining with antiCD36 antibody, the results
revealed that the CD36 proteins collectively existed in cel-
lular membrane and GFPs, however, were concentrated in
the cytoplasm (Fig. 2). Then, we assayed whether the
fusion to the GFP protein could have influence on the
physiological function of CD36 in the recombinant pro-
teins. Firstly, we attempted to detect if co-expressed GFP
Quantitative assays of GFP and CD36 expression Figure 3
Quantitative assays of GFP and CD36 expression. The 
procedures of transfection were same as in Fig. 2. After 
transfection for 48 hours, cells were washed three times 
with PBS and then fixed with 4% paraformaldehyde for 30 
min and then assayed under flow cytometry. The results are 
a summary of three independent experiments.
Confocal microscopy to observe both GFP and huCD36 pro- tein expression Figure 2
Confocal microscopy to observe both GFP and 
huCD36 protein expression. Constructs of pEGFP-C3-
CD36, pEGFP-N3-CD36, and pEGFP-N3 vector alone, were 
transit-transfected into CHO cells for 48 hours, and the 
transfected cells were then immunostained with anti-CD36 
antibody, counter-stained with TRIC-conjugated anti-mouse 
IgG secondary antibody. After washing several times, cells 
were mounted on slides and observed under confocal micro-
scope. Top panel: pEGFP-N3 transfected alone; Middle panel: 
cells transfected with pEGFP-C3-CD36; Bottom panel: 
pEGFP-N3-CD36 transfected. Both GFP and CD36 were 
expressed in two constructs.Lipids in Health and Disease 2007, 6:24 http://www.lipidworld.com/content/6/1/24
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proteins could modify Ox-LDL binding on CD36. Two
kinds of binding assay methods, uptake and surface bind-
ing, were carried out. To our surprise, p-EGFP-N3-CD36
showed a normal binding to OxLDL in both of the binding
assays. However, pEGFP-C3-CD36 showed almost no
OxLDL binding in uptaking, and a much increased surface
binding. Then we assayed for pRBC binding and the results
confirmed that CD36 proteins expressed from both
pEGFP-C3-CD36 and pEGFP-N3-CD36 showed normal
adhesion to pRBCs (Fig. 6), and their bindings are similar
to those as observes in normal CD36 expressing cells [20].
CD36 has been well defined as a membrane receptor that
can function as a molecule with specificity for multiple
ligands including collagen, pRBCs, TSP, apoptotic cells
and modified lipoproteins [25,32,35,37]. Several earlier
reports suggested that each ligand has a discrete non-con-
tiguous region on CD36 molecule that may be spatially
proximal. OxLDL bound to an immobilized fusion pro-
tein containing the amino-termini of p6–143 and p28–93
showed an approximately similar affinity as intact CD36
[26], which provided a conclusive evidence for oxLDL
binding domain at P28–93 on CD36. However, the
amino acid region at 93–120 was only for the TSP bind-
ing, but not for oxLDL binding [38,39]. In contrast, one
report by using a chimeric CD36 construct with the
murine sequence 155 – 183 substituting the equivalent
human sequence suggested that the p155–183 domain
may be critical for oxLDL binding [29]. Crandall et al
(1999) reported that OxLDL competitively inhibits the
adherence of pRBCs to CD36 but they suggest that,
although oxLDL competitively inhibits the adherence of
pRBCs, these ligand interact with distinct domains on the
CD36 receptor [20]. Imach et al (2000) reported that the
scavenger receptor class A, CD36, or CD68 can specifically
recognize damaged apoptotic cells and they may play a
major role in the clearance of apoptotic cells in the thy-
mus, mediating the recognition and ingestion of apop-
totic thymocytes [40]. All of the above reports seemed to
come to a conclusion that CD36 embeds specific regions
for binding of different ligands and some of them may co-
interact. By sequence alignment of CD36 proteins from
different species and other CD36 gene family members
Deficiency of uptake oxLDL by pEGFP-C3-CD36 was par- tially rescued by surface binding Figure 5
Deficiency of uptake oxLDL by pEGFP-C3-CD36 was 
partially rescued by surface binding. The transfection 
was same as described in Fig. 4. After 48 hours of transfec-
tion, cells were rinsed with PBS twice and fixed with 4% 
paraformaldehyde for 30 min, and then incubated with Dil-
OxLDL at 10 μg/ml for 2 hours at room temperature. After 
washed for three times with PBS, cells were collected and 
assayed with flow cytometry. The results are an average of 
three experiments. Dark box: oxLDL uptaking and grey box: 
oxLDL surface binding.
pEGFP-C3-CD36 limited OxLDL uptake, but not for pEGFP- N3-CD36 Figure 4
pEGFP-C3-CD36 limited OxLDL uptake, but not for 
pEGFP-N3-CD36. pEGFP-C3-CD36 and pEGFP-N3-
CD36, as well as pEGFP-N3 alone were transit-transfected 
into CHO cells. After transfection for 48 hours, cells were 
rinsed twice with PBS and Dil-oxLDL at 10 μg/ml was incu-
bated with the transfected cells for 1 hour. After rinsed for 
three times with PBS, cells were mounted on coverlids and 
observed under confocal microscope. Typical transfected 
and Dil-oxLDL was photographed. Dil-oxLDL was only 
weakly bound to pEGFP-C3-CD36 transfected cells.Lipids in Health and Disease 2007, 6:24 http://www.lipidworld.com/content/6/1/24
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the N-terminal region from the amino acid 31–190 shows
significant sequence conservation indicative of its func-
tional importance [26], possibly in oxLDL binding.
The approach using recombinant fusion protein seemed
to be a potent technique to detect specific amino acid
domains and to analyze protein-protein interaction
[26,30]. In our study, we used GFP-tagged to CD36 to
investigate if the CD36 could be expressed in CHO cells
and if GFP could affect CD36 function to interact with
oxLDL and pRBCs. We choose to use GFP as fusion pro-
teins based on the following reasons: The green fluores-
cent proteins (GFP), have been recently used for many
cellular biology approaches to investigate target proteins'
localization, physiological function and signal transduc-
tion, as well as gene expression [41,42]. Typically, pro-
teins tagged to GFP were used to detect protein
localization in living cells [43]. Also, GFP as a marker was
used for gene expression [44], protein trafficking and
secretion [45], and apoptosis assays [45,46]. Also GFP was
extended to assay cellular physiological changes of
enzyme activities and signal transduction [47,48]. In this
study, our results observed that when CD36 attached to
the C-terminal of GFP, binding of ox-LDL was deleted, but
when CD36 was attached to the N-terminal, there is no
much effect on ox-LDL binding. There are two possibili-
ties that may cause this to happen: (1) the Ox-LDL bind-
ing domain is located at the N-terminal of CD36 and it
closely contacts with GFP proteins, the expressed GFP pro-
teins may directly affect oxLDL binding via protein-pro-
tein interaction, or change of protein conformation; (2)
the expressed GFP proteins may directly or indirectly
affected CD36 protein's physiological function. This find-
ing indicated that preventing of atherosclerosis could be
achieved via CD36 protein recombination.
Acknowledgements
This work was carried out at Dr. Ian Crandall's laboratory under his super-
vision and financial support. We sincerely thank Dr Kevin Kain, Graham F. 
Maguire, Philip W. Connelly for their helps during the manuscript prepara-
tion.
References
1. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Tay-
lor K, Horkko S, Palinski W, Quehenberger O, Shaw P, Steinberg D,
Terpstra V, Witztum JL: Scavenger receptors, oxidized LDL,
and atherosclerosis.  Ann N Y Acad Sci 2001, 947:214-22; discussion
222-3.
2. Boyle JJ: Macrophage activation in atherosclerosis: pathogen-
esis and pharmacology of plaque rupture.  Curr Vasc Pharmacol
2005, 3(1):63-68.
3. Steinberg D: A docking receptor for HDL cholesterol esters.
Science 1996, 271(5248):460-461.
4. Daugherty A: Atherosclerosis: cell biology and lipoproteins.
Curr Opin Lipidol 1998, 9(6):613-615.
5. Herijgers N, Van Eck M, Korporaal SJ, Hoogerbrugge PM, Van Berkel
TJ: Relative importance of the LDL receptor and scavenger
receptor class B in the beta-VLDL-induced uptake and accu-
mulation of cholesteryl esters by peritoneal macrophages.  J
Lipid Res 2000, 41(7):1163-1171.
6. Fukasawa M, Adachi H, Hirota K, Tsujimoto M, Arai H, Inoue K:
SRB1, a class B scavenger receptor, recognizes both nega-
tively charged liposomes and apoptotic cells.  Exp Cell Res 1996,
222(1):246-250.
7. Platt N, da Silva RP, Gordon S: Recognizing death: the phagocy-
tosis of apoptotic cells.  Trends Cell Biol 1998, 8(9):365-372.
8. Nicholson AC, Hajjar DP: CD36, oxidized LDL and PPAR
gamma: pathological interactions in macrophages and
atherosclerosis.  Vascul Pharmacol 2004, 41(4-5):139-146.
9. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S,
Nakayama H: CD36, a member of class B scavenger receptor
family, is a receptor for advanced glycation end products.
Ann N Y Acad Sci 2001, 947:350-355.
10. Calvo D, Dopazo J, Vega MA: The CD36, CLA-1 (CD36L1), and
LIMPII (CD36L2) gene family: cellular distribution, chromo-
somal location, and genetic evolution.  Genomics 1995,
25(1):100-106.
11. Huh HY, Lo SK, Yesner LM, Silverstein RL: CD36 induction on
human monocytes upon adhesion to tumor necrosis factor-
activated endothelial cells.  J Biol Chem 1995, 270(11):6267-6271.
12. Husemann J, Obstfeld A, Febbraio M, Kodama T, Silverstein SC:
CD11b/CD18 mediates production of reactive oxygen spe-
cies by mouse and human macrophages adherent to
matrixes containing oxidized LDL.  Arterioscler Thromb Vasc Biol
2001, 21(8):1301-1305.
13. Nakata A, Nakagawa Y, Nishida M, Nozaki S, Miyagawa J, Nakagawa
T, Tamura R, Matsumoto K, Kameda-Takemura K, Yamashita S, Mat-
suzawa Y: CD36, a novel receptor for oxidized low-density
lipoproteins, is highly expressed on lipid-laden macrophages
in human atherosclerotic aorta.  Arterioscler Thromb Vasc Biol
1999, 19(5):1333-1339.
14. Armstrong LC, Bornstein P: Thrombospondins 1 and 2 function
as inhibitors of angiogenesis.  Matrix Biol 2003, 22(1):63-71.
Both N- and C-terminal tagged huCD36 bind normally to  pRBCs Figure 6
Both N- and C-terminal tagged huCD36 bind nor-
mally to pRBCs. After transfection with pEGFP-C3-CD36, 
pEGFP-N3-CD36 or pEGFP-N3 alone, cells were fixed with 
4% paraformaldehyde for 20 min and then rinsed twice with 
PBS. The cells were then incubated with pRBCs for 4 hours 
at room temperature with gent shacking. pRBCs bindings 
were observed under fluorescent microscope and typical 
binding cells were photographed. pRBCs were bound to both 
pEGFP-C3-CD36 and pEGFP-N3-CD36 transfected cells.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Lipids in Health and Disease 2007, 6:24 http://www.lipidworld.com/content/6/1/24
Page 7 of 7
(page number not for citation purposes)
15. Simantov R, Silverstein RL: CD36: a critical anti-angiogenic
receptor.  Front Biosci 2003, 8:s874-82.
16. Kopprasch S, Pietzsch J, Westendorf T, Kruse HJ, Grassler J: The
pivotal role of scavenger receptor CD36 and phagocyte-
derived oxidants in oxidized low density lipoprotein-induced
adhesion to endothelial cells.  Int J Biochem Cell Biol 2004,
36(3):460-471.
17. Fernandez-Ruiz E, Armesilla AL, Sanchez-Madrid F, Vega MA: Gene
encoding the collagen type I and thrombospondin receptor
CD36 is located on chromosome 7q11.2.  Genomics 1993,
17(3):759-761.
18. Sexton DW, Al-Rabia M, Blaylock MG, Walsh GM: Phagocytosis of
apoptotic eosinophils but not neutrophils by bronchial epi-
thelial cells.  Clin Exp Allergy 2004, 34(10):1514-1524.
19. Fadok VA, Bratton DL, Frasch SC, Warner ML, Henson PM: The
role of phosphatidylserine in recognition of apoptotic cells by
phagocytes.  Cell Death Differ 1998, 5(7):551-562.
20. Crandall I, Guy RA, Maguire GF, Connelly PW, Kain KC: Plasmo-
dium falciparum-infected erythrocytes and oxidized low-
density lipoprotein bind to separate domains of CD36.  J Infect
Dis 1999, 180(2):473-479.
21. Batt KV, Patel L, Botham KM, Suckling KE: Chylomicron remnants
and oxidised low density lipoprotein have differential effects
on the expression of mRNA for genes involved in human
macrophage foam cell formation.  J Mol Med 2004,
82(7):449-458.
22. Beeson JG, Brown GV: Plasmodium falciparum-infected eryth-
rocytes demonstrate dual specificity for adhesion to
hyaluronic acid and chondroitin sulfate A and have distinct
adhesive properties.  J Infect Dis 2004, 189(2):169-179.
23. Bottcher A, Gaipl US, Furnrohr BG, Herrmann M, Girkontaite I, Kal-
den JR, Voll RE: Involvement of phosphatidylserine,
alphavbeta3, CD14, CD36, and complement C1q in the
phagocytosis of primary necrotic lymphocytes by macro-
phages.  Arthritis Rheum 2006, 54(3):927-938.
24. Ryeom SW, Sparrow JR, Silverstein RL: CD36 participates in the
phagocytosis of rod outer segments by retinal pigment epi-
thelium.  J Cell Sci 1996, 109 ( Pt 2):387-395.
25. Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA:
Human CD36 is a high affinity receptor for the native lipo-
proteins HDL, LDL, and VLDL.  J Lipid Res 1998, 39(4):777-788.
26. Pearce SF, Roy P, Nicholson AC, Hajjar DP, Febbraio M, Silverstein
RL: Recombinant glutathione S-transferase/CD36 fusion pro-
teins define an oxidized low density lipoprotein-binding
domain.  J Biol Chem 1998, 273(52):34875-34881.
27. Nicholson AC, Frieda S, Pearce A, Silverstein RL: Oxidized LDL
binds to CD36 on human monocyte-derived macrophages
and transfected cell lines. Evidence implicating the lipid moi-
ety of the lipoprotein as the binding site.  Arterioscler Thromb
Vasc Biol 1995, 15(2):269-275.
28. Tao N, Wagner SJ, Lublin DM: CD36 is palmitoylated on both N-
and C-terminal cytoplasmic tails.  J Biol Chem 1996,
271(37):22315-22320.
29. Puente Navazo MD, Daviet L, Ninio E, McGregor JL: Identification
on human CD36 of a domain (155-183) implicated in binding
oxidized low-density lipoproteins (Ox-LDL).  Arterioscler
Thromb Vasc Biol 1996, 16(8):1033-1039.
30. Stewart BW, Nagarajan S: Recombinant CD36 inhibits oxLDL-
induced ICAM-1-dependent monocyte adhesion.  Mol Immunol
2006, 43(3):255-267.
31. Stewart CR, Tseng AA, Mok YF, Staples MK, Schiesser CH, Lawrence
LJ, Varghese JN, Moore KJ, Howlett GJ: Oxidation of low-density
lipoproteins induces amyloid-like structures that are recog-
nized by macrophages.  Biochemistry 2005, 44(25):9108-9116.
32. Boullier A, Friedman P, Harkewicz R, Hartvigsen K, Green SR, Alma-
zan F, Dennis EA, Steinberg D, Witztum JL, Quehenberger O: Phos-
phocholine as a pattern recognition ligand for CD36.  J Lipid
Res 2005, 46(5):969-976.
33. Armesilla AL, Calvo D, Vega MA: Structural and functional char-
acterization of the human CD36 gene promoter: identifica-
tion of a proximal PEBP2/CBF site.  J Biol Chem 1996,
271(13):7781-7787.
34. Pearce SF, Wu J, Silverstein RL: A carboxyl terminal truncation
mutant of CD36 is secreted and binds thrombospondin: evi-
dence for a single transmembrane domain.  Blood 1994,
84(2):384-389.
35. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Prot-
ter AA: CD36 is a receptor for oxidized low density lipopro-
tein.  J Biol Chem 1993, 268(16):11811-11816.
36. Calvo D, Gomez-Coronado D, Lasuncion MA, Vega MA: CLA-1 is
an 85-kD plasma membrane glycoprotein that acts as a high-
affinity receptor for both native (HDL, LDL, and VLDL) and
modified (OxLDL and AcLDL) lipoproteins.  Arterioscler Thromb
Vasc Biol 1997, 17(11):2341-2349.
37. Fidge NH: High density lipoprotein receptors, binding pro-
teins, and ligands.  J Lipid Res 1999, 40(2):187-201.
38. Frieda S, Pearce A, Wu J, Silverstein RL: Recombinant GST/CD36
fusion proteins define a thrombospondin binding domain.
Evidence for a single calcium-dependent binding site on
CD36.  J Biol Chem 1995, 270(7):2981-2986.
39. Yabkowitz R, Dixit VM: Human carcinoma cells express recep-
tors for distinct domains of thrombospondin.  Cancer Res 1991,
51(6):1645-1650.
40. Imachi H, Murao K, Hiramine C, Sayo Y, Sato M, Hosokawa H, Ishida
T, Kodama T, Quehenberger O, Steinberg D, Takahara J: Human
scavenger receptor B1 is involved in recognition of apoptotic
thymocytes by thymic nurse cells.  Lab Invest 2000,
80(2):263-270.
41. Misteli T, Spector DL: Applications of the green fluorescent
protein in cell biology and biotechnology.  Nat Biotechnol 1997,
15(10):961-964.
42. Misteli T, Caceres JF, Spector DL: The dynamics of a pre-mRNA
splicing factor in living cells.  Nature 1997, 387(6632):523-527.
43. Breidert S, Jacob R, Ngezahayo A, Kolb HA, Naim HY: Trafficking
pathways of Cx49-GFP in living mammalian cells.  Biol Chem
2005, 386(2):155-160.
44. Kosaka S, Takuma H, Tomiyama T, Mori H: The distributions of
tau short and long isoforms fused with EGFP in cultured
cells.  Osaka City Med J 2004, 50(1):19-27.
45. Kaether C, Salm T, Glombik M, Almers W, Gerdes HH: Targeting
of green fluorescent protein to neuroendocrine secretory
granules: a new tool for real time studies of regulated pro-
tein secretion.  Eur J Cell Biol 1997, 74(2):133-142.
46. Strebel A, Harr T, Bachmann F, Wernli M, Erb P: Green fluorescent
protein as a novel tool to measure apoptosis and necrosis.
Cytometry 2001, 43(2):126-133.
47. Persechini A, Lynch JA, Romoser VA: Novel fluorescent indicator
proteins for monitoring free intracellular Ca2+.  Cell Calcium
1997, 22(3):209-216.
48. Romoser VA, Hinkle PM, Persechini A: Detection in living cells of
Ca2+-dependent changes in the fluorescence emission of an
indicator composed of two green fluorescent protein vari-
ants linked by a calmodulin-binding sequence. A new class of
fluorescent indicators.  J Biol Chem 1997, 272(20):13270-13274.